Uloric Lawsuit


Looking for representation in the Uloric lawsuit? Our experience, expertise, and resources make Hollis Law the ideal partner.

Contact Us

Looking for representation in the Uloric lawsuit? Our experience, expertise, and resources make Hollis Law the ideal partner.

Call the Hollis Law Firm at 1-800-701-3672 if you or a loved one has taken this medication since 2013 and developed cancer. All calls and case evaluations are free and carry no obligation. The Hollis Law Firm works on cases on a contingent fee basis, which means we don’t get paid if you don’t get paid. Call 1-800-701-3672 to speak to one of our trained intake specialist so that your potential cancer claim can be reviewed by an attorney at the Hollis Law Firm. The injuries and damages caused by contaminated products will not be uniform; therefore, claims will need to proceed on an individual basis and not as part of a class action.


Uloric (Febuxostat) is a drug commonly prescribed for the management of chronic hyperuricemia in adults with gout. Takeda Pharmaceuticals, the manufacturer of Uloric, may have failed to warn users of this medication of the increased risk of heart attacks and strokes, resulting in a Uloric lawsuit.

History of the Case

Our Uloric lawsuit attorneys are currently investigating potential claims for those who have experienced the following injuries after using the drug Uloric:

  • Heart Attack
  • Heart-related Death
  • Deep-vein Thrombosis
  • Angioplasty

Injuries Related to Product

Gout is a form of arthritis, commonly occurring in the feet and toes, which results from elevated uric acid levels in the bloodstream. This elevated level of uric acid in the body can lead to sudden, severe attacks of pain, swelling, and tenderness in the joints.

Uloric blocks the metabolic processes in the body that create uric acid, therefore relieving pain and inflammation in the joints. If you’ve experienced this issue, you may have a place in our Uloric lawsuit.

Additional Literature

Deadly Findings of Uloric

Uloric is manufactured by Takeda Pharmaceuticals and hit the market as soon as it gained FDA approval in February 2009. After approval, the FDA required Takeda to conduct a post-market safety clinical trial due to unanswered questions and continued cardiovascular concerns.

The preliminary results of the 6,000-patient study were published on March 2018 in The New England Journal of Medicine. The results concluded Uloric posed a significantly increased risk of cardiovascular-related death, heart attacks, and strokes compared to users of allopurinol. If you or a loved one has experienced one of these problems, you we can represent you in the Uloric lawsuit… Continued
FDA Updated Safety Notices

Updated Safety Notice released in November 2017:

The FDA released an updated safety notice regarding the increased risk of heart-related injuries and death. 

Updated Safety Notice released in Feburary 2019:

The FDA issues another updated safety notice which included a black box warning regarding the increased risk for heart attacks and death.

Do I Have a Case?

Give us a few details about your concerns and our case tool will help you get the answers you need.

Get Started